Search clinical trials for: Standard Dose Quadrivalent Inactivated Influenza Vaccine

Total 497 results

National Institute of Allergy and Infectious Diseases...

Completed

Comparison of Flu Vaccine Doses in Children

Influenza

United States
Neufeld, Ellis J, MD, PhD
Terrana ITP Research Fund

Completed

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura | Immune Thrombocytopenic Purpura

United States
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Herpes Zoster

Germany, Canada, United States
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

Herpes Zoster

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children

Influenza

Spain, Taiwan, Canada, United States, Mexico
McMaster University
Canadian Institutes of Health Research (CIHR)

Completed

Live Versus Inactivated Influenza Vaccine Study in Hutterite Children

Influenza

Canada
Pfizer

Completed

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

United States
Sinovac Life Sciences Co., Ltd.

Completed

Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19

COVID-19

China
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

Influenza

United States
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Influenza | Pandemic Influenza

Austria, Germany
The University of Hong Kong
Research Grants Council, Hong Kong; Research Fund for the Control of Infectious... and other collaborators

Completed

Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children

Influenza Virus Infection

China
National Institute of Allergy and Infectious Diseases...

Completed

H9 Priming Study in Healthy Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects

Seasonal Influenza

Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects

Influenza

Italy
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Influenza

United States
Ology Bioservices

Completed

Yearly Strain Variation Study, 2010/2011

Influenza | Seasonal Influenza

Austria
Centre Hospitalier Universitaire de Nice

Recruiting

Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX (CHRONOVAX)

Vaccination; Infection

France
Roswell Park Cancer Institute

Completed

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Higher Dose Intradermal H5 Vaccine

Influenza

United States
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
Sanofi

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

United States
Dalhousie University
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR); IWK Health Centre

Completed

Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children

Seasonal Influenza

Canada
Baylor College of Medicine
National Institute of Allergy and Infectious Diseases (NIAID); Novartis; Sanofi... and other collaborators

Completed

Control of Epidemic Influenza Through a School-based Influenza Vaccination Program (CEI)

Influenza

United States
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pediatric Second Influenza Dose Portal Reminder Recall

Respiratory Tract Infections | Influenza

United States
Medicago

Completed

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Adults

Influenza | Pandemic Influenza

Austria, Germany
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants

Human Parainfluenza Virus 2

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China

Influenza

China
Beijing Chaoyang District Centre for Disease Control...

Unknown

Safety Study of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in Chinese Adults Aged 3 Years and Older

Influenza
Emory University
National Cancer Institute (NCI); Sanofi; National Institutes of Health (NIH)

Completed

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

Plasma Cell Neoplasm

United States
The Jackson Laboratory
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Recruiting

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults (FluVax3)

Aging | Influenza Vaccine | Vaccine Response | Dendritic Cell

United States
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Influenza Immunisation | Avian Influenza

United States
CureVac

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

Rabies

Belgium, Germany
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Influenza

Taiwan
Ology Bioservices
Baxter Innovations GmbH

Completed

Japanese Pediatric H5N1 Vaccine Study

Influenza

Japan
The University of Texas Medical Branch, Galveston
Cancer Prevention Research Institute of Texas

Active, not recruiting

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

Efficacy | Human Papilloma Virus | Immunization

United States
University of Vermont
World Health Organization

Active, not recruiting

Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT

Poliomyelitis

United States
Health Institutes of Turkey
TC Erciyes University; Mene Research; Kocak Farma

Not yet recruiting

Evaluation of the Efficacy, Safety and Immunogenicity of Inactivated COVID 19 Vaccine(TURKOVAC) in Healthy Population of 18 and 64 Years of Age (Both Inclusive):a Randomized, Double-blind, Phase IIb Clinical Trial

Covid19

Turkey
Ology Bioservices

Completed

Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine

Influenza | Pandemic Influenza

Austria
Ology Bioservices
Baxter Innovations GmbH

Completed

H5N1 Vaccine Study in Japanese Adults

H5N1 Influenza

Japan
Novartis Vaccines

Completed

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects

Influenza

Italy
Novavax

Terminated

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Influenza, Human

United States
MedImmune LLC

Terminated

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Australia, Korea, Republic of, Peru, Canada, Israel
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

Glioma | Astrocytoma | Oligodendroglioma

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Influenza

Korea, Republic of
Bassett Healthcare
New York State Department of Health

Completed

Duration of Immune Response to Influenza Vaccination in Patients With RA

Rheumatoid Arthritis

United States

3

Subscribe